Holiday Sale | Save 50%
Holiday Sale | Save 50%
Published

UK firm GSK to pay $2.2bn over Zantac cancer claims

  • UK firm GSK agrees to pay $2.2 billion to settle claims that its heartburn drug Zantac caused cancer, involving around 80,000 claimants in the US.
  • GSK will also pay $70 million to settle a whistleblower complaint claiming it concealed Zantac's cancer risks from the US government.
  • The settlements, which do not include an admission of wrongdoing, aim to address financial uncertainty from ongoing litigation.
Insights by Ground AI
Does this summary seem wrong?
Think freely.Subscribe and get full access to Ground NewsSubscriptions start at $9.99/yearSubscribe

Bias Distribution

  • 67% of the sources are Center
Factuality

To view factuality data please Upgrade to Premium

Ownership

To view ownership data please Upgrade to Vantage

Sources are mostly out of (0)